



Claims

1. Chimeric oligonucleotides of a general formula I for binding telomerase, comprising,



wherein R is selected from the group consisting of



wherein

n is at least 10 and not more than 20,

R_1 is selected from the group consisting of S^- , CH_3 , and O^- ,

B is selected from the group consisting of thymine, cytosine, adenine, and guanine,

n_1 is at least 3 and not more than 17,

B_1 is selected from the group consisting of thymine, cytosine, adenine, guanine, 5-propyluracil, and 5-propylcytosine,


R_2 is selected from the group consisting of H, F, NH_2 , O-alkyl ($\text{C}_1 - \text{C}_5$), O-allyl, and O-methoxyethoxy,

R_3 is selected from the group consisting of NH and O, wherein if R_3 is NH, R_2 must not be selected from the group consisting of NH_2 , O-alkyl ($\text{C}_1 - \text{C}_5$), O-allyl, and O-methoxyethoxy,


R_4 is selected from the group consisting of 2',3'-dideoxy-3'-fluoroguanosine, 2',3'-dideoxy-3'-azidoguanosine, 2',3'-dideoxy-3'-aminoguanosine, 2',3'-epoxyguanosine, acyclovir, gancyclovir, 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, and 2'-deoxythymidine,

L is selected from the group consisting of $-(\text{PO}_2)-\text{OCH}_2-\text{COH}-\text{CH}_2-\text{NH}-$ and $-(\text{PO}_2)-\text{OCH}_2-\text{CH}(\text{CH}_2\text{COOH})-(\text{CH}_2)_4\text{NH}-$.


2. The oligonucleotides according to claim 1, wherein R is



3. The oligonucleotides according to claim 1, wherein R is



4. The oligonucleotides according to claim 1, wherein R is



5. The oligonucleotides according to claim 1, wherein R1 to R4 and B and B1 vary from a nucleotide unit to another nucleotide unit.

6. The oligonucleotides according to claim 1, wherein the oligonucleotides having a nucleotide sequence is selected from the group consisting of

5'-TCAGATTAGTACTCGTCAGAGTTAGGGTTAG-3' (SEQ ID No. 1)

5'-TCAGATTAGGACTGCTCAGAGTTAG-3' (SEQ ID No. 2)

5'-TCAGATTAGTACTCGTCAGACAGTTAGGGTTAG-3' (SEQ ID No. 3)

5'-TCAGATTAGTACTCGTCAGAGTTAGAGTTAG-3' (SEQ ID No. 4)
 5'-TCAGATTAGGACTGCTCAGAGUUAG-3' (SEQ ID No. 5)
 5'-TCAGATTAGGACTGCTCAGAUAGUUAG3' (SEQ ID No. 6)
 5'-TCAGATTAGGACTGCTCAGAGUUAGGGTTAGACAA-3' (SEQ ID No. 7)
 5'-TCAGATTAGGACTGCGTTAGGGTTAGACAA-3' (SEQ ID No. 8)
 5'-TCAGATTAGTACTCGTCAGA-O(PO₂)OCH₂CH(CH₂COOH-(CH₂))₄-NH-TAGGGTTAGACAA-3' (SEQ ID No. 9)
 5'-TCAGATTAGTACTCGTCAGAGTTAGGGTTA-azidodeoxyguanosine-3' (SEQ ID No. 10)
 5'-AATCCTCCCCCAGTTCACCC- GTTAGGGT-3' (SEQ ID No. 11)
 5'-TCTCCCAGCGTGCGCCAT- GUUAGGGUUAG-3' (SEQ ID No. 12)
 5'-ATGTATGCTGTGGCT- n(L) -GTTAGG-3' (SEQ ID No. 13)
 5'- GTACTGCTCAGA-GTTAGGGTTAG-3' (SEQ ID No. 14)
 5'- GTACTGCTCAGA-GTTAGGGT-3' (SEQ ID No. 15)
 5'- GTACTGCTCAGA-GUUAGGGUUAG-3' (SEQ ID No. 16)
 5'- GTACTGCTCAGA-n(L)-GTTAGG-3' (SEQ ID No. 17)
 5'-GGCCAGCAGCTG- GUUAGGGUUAG-3' (SEQ ID No. 18)
 5'- TGCTCAGA-GUUAGGGUUAG-3' (SEQ ID No. 19)
 5'- TGCTCAGA-n(L)-GTTAGG-3' (SEQ ID No. 20)
 5'- TCAGACATATACTGCTCAGA-n(L)-TAGGGTTAGACAA-3' (SEQ ID No. 21)
 5'- ACT GCT CAG A-GTT AG-3' (SEQ ID No. 22)
 5'- ACT GCT CAG A-GUU AGG GUU AG-3' (SEQ ID No. 23)
 5'- ATA CTG CTC AGA-linker-GTT AGG GTT AG-3' (SEQ ID No. 24)
 5'- TTA GTA CTG CTC AGA-GTT AGG GTT AG-3' (SEQ ID No. 25)
 5'- TCA GAT TAG TAC TGC TCA GA-GTT AG-3' (SEQ ID No. 26)
 5'- TCA GAT TAG TAC TGC TCA GA-GTT AG-3' (SEQ ID No. 27)
 5'-ACT GCT CAG A-GTT AGGGTTAG-3' (SEQ ID No. 28)
 5'-TTAGGG-3' (SEQ ID No. 29).

7. A method of inhibiting telomerase activity, comprising the administering of chimeric oligonucleotides to a human tumor cell line.

8. A method of in vivo treatment of tumours, comprising the administering of chimeric oligonucleotides in a flank region.

add A' >